Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre.
In this retrospective study, we analyzed the effect of the presence of anti-donor preformed alloantibodies in 268 liver allograft transplants. Crossmatches were performed by complement-dependent cytotoxicity (CDC) assay and HLA antibody screening by flow cytometry (FlowPRA). Positive anti-donor crossmatch was detected in 5.2% of transplants. Acute rejection frequency in +CDC crossmatch patients was not different from that observed in -CDC crossmatch patients. None of the patients transplanted with +CDC crossmatch developed chronic rejection, but they showed a significantly lower allograft survival rate, and the majority of them had allograft failures before the end of the first post-transplant year, mainly within the 3 first months. Indeed, positive FlowPRA determination was concordant with data from the CDC assay. In conclusion, these findings show a direct correlation between the presence of anti-donor preformed antibodies and a poor allograft survival in liver transplant.
Muro
Manuel
M
Immunology Service, University Hospital Virgen de la Arrixaca, Murcia 30120, Spain. manuel.muro@carm.es
Marin
Luis
L
Miras
Manuel
M
Moya-Quiles
Rosa
R
Minguela
Alfredo
A
Sánchez-Bueno
Francisco
F
Bermejo
Juan
J
Robles
Ricardo
R
Ramírez
Pablo
P
García-Alonso
Ana
A
Parrilla
Pascual
P
Alvarez-López
María R
MR
D000961:Antilymphocyte Serum / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000097:blood* / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000628:therapy*; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D011379:Prognosis; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D015415:Biomarkers